This document reports a heterogeneous polypeptide, including the first polypeptide, in the direction from N-terminal to C-terminal, at least a part of immunoglobulin in bisagra region, including one or more epoxide terminals, one innoglobulina CH2 domain and one CH3 immunoglobulin domain, and The second polypeptide, in the direction from N-terminal to C-terminal, includes at least one part of double immunoglobulin region, including one or more epoxide remains, one N2 immunoglobulin region and one N3 immunoglobulin region. The first polypeptide includes mutation y349c, t366s,L368a and y407v (ojal chain) and the second polypeptide include s354c and t366w (button chain) mutations,The first polypeptide (fabric chain) includes mutation (I) i253a or i253g, and (II) l314a or l314g or l314d, wherein the first polypeptide and the second polypeptide are connected by one or more disulfuro bridges, The CH3 dominance of the first peptide and the CH3 dominance of the second peptide either bind to or not bind to the protein (according to Kabat EU index number). 13. Claim 13: a medicament including heteromorphic polypeptideIn accordance with any of the requirements of paragraphs 1 to 12, an acceptable vehicle on the drug may also be selected. Claim 15: polybrominated diphenyl ether for the treatment of eye diseases in accordance with any one of claims 1 to 12It's better to have vascular disease of the eyeEn el presente documento se informa de un polipéptido heterodimérico que comprende un primer polipéptido que comprende, en dirección N-terminal a C-terminal, al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más restos de cisteína, un dominio CH2 de imnunoglobulina y un dominio CH3 de inmunoglobulina, y un segundo polipéptido que comprende, en dirección N-terminal a C-terminal, al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más restos de cisteína, un dominio CH2 de inmunoglobulina y un dominio CH3 de inmunoglobu
